Navigation Links
Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference
Date:5/17/2013

SEATTLE, May 17, 2013 /PRNewswire/ -- Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that Kyle Guse , Chief Financial Officer & General Counsel, will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013, in New York City at the Grand Hyatt Hotel.

The Company's presentation is scheduled to begin at 3:30 p.m. EDT and will be available via a live webcast. To access the webcast, go to www.atossagenetics.com.

For more information and registration, please visit the conference website: http://www.marcumllp.com/microcap.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS; www.atossagenetics.com), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented diagnostic medical devices and patented laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA.  The NRLBH provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating breast cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum LLP offers the resources of 1,000 professionals, including over 125 partners, in more than 20 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein & Pinchuk LLP; MarcumBuchanan Associates LLC; and Marcum Cronus Partners LLC.

Investor or Corporate Contacts:

Atossa Genetics, Inc.
Kyle Guse
(800) 351-3902
Kyle.Guse@atossagenetics.com

Matthew D. Haines
MBS Value Partners
(212) 710-9686
Matt.Haines@mbsvalue.com


'/>"/>
SOURCE Marcum LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Millennium HealthCare Signs Distribution Agreement with Atossa Genetics
2. Metamark Genetics Board of Directors Appoints Shawn M. Marcell President and Chief Executive Officer
3. NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference
4. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
5. NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call
6. NewLink Genetics Corporation Announces Exercise of Underwriters Option and Closing of Public Offering of Common Stock
7. NewLink Genetics Corporation Announces Pricing of Public Offering of Common Stock
8. NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock
9. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
10. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
11. Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... May 21, 2020 , ... Rapid Application Group (RAG), ... deliver thousands of critical Personal Protection Equipment (PPE) devices to local first responders ... work, the three companies teamed together to start production of face shields and ...
(Date:5/21/2020)... ... 2020 , ... MedTech Breakthrough , an independent market ... health and medical technology market, today announced that Hospital IQ , the ... of its “Health Administration Innovation Award” in the fourth annual MedTech Breakthrough Awards ...
(Date:5/21/2020)... ... ... Murrieta Genomics has partnered with Life Science Nation ... companies a special discount rate to the Digital RESI 3-Day Global Conference being held ... to bring together startups with early-stage investors and strategic channel partners. The goal was ...
Breaking Medicine Technology:
(Date:5/26/2020)... ... May 26, 2020 , ... ... can impact the brain causing post infectious encephalitis. The work was conducted ... and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) could adversely attack the central nervous ...
(Date:5/25/2020)... ... May 23, 2020 , ... Winemaker Grant Long Jr. is ... to present something whimsical and delicious in these complicated times,” he said, in announcing ... and 2018 Grenache ($24.99). The Chardonnay and Red Wine Blend are sourced in the ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... experience of GSCG, VITA NOVAS has already gained ground with the inherited reputation ... and stimulating biological products intravenously, guaranteeing an effective way for the ingredients to ...
(Date:5/21/2020)... Fla. (PRWEB) , ... May 21, 2020 , ... The ... normal, there have been a lot of complications and adjustments, needless to say, more ... the highest level since the great depression it can be hard to escape and ...
(Date:5/16/2020)... ... 2020 , ... For patients who have gone to see Andy Gaertner, D.M.D , in ... had in place. After being allowed to re-open during the current pandemic, they have put ... as safe and comfortable as possible while going through their dental exams and treatments. , ...
Breaking Medicine News(10 mins):